These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38750034)

  • 1. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.
    Segal NH; Melero I; Moreno V; Steeghs N; Marabelle A; Rohrberg K; Rodriguez-Ruiz ME; Eder JP; Eng C; Manji GA; Waterkamp D; Leutgeb B; Bouseida S; Flinn N; Das Thakur M; Elze MC; Koeppen H; Jamois C; Martin-Facklam M; Lieu CH; Calvo E; Paz-Ares L; Tabernero J; Argilés G
    Nat Commun; 2024 May; 15(1):4091. PubMed ID: 38750034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.
    Gonzalez-Exposito R; Semiannikova M; Griffiths B; Khan K; Barber LJ; Woolston A; Spain G; von Loga K; Challoner B; Patel R; Ranes M; Swain A; Thomas J; Bryant A; Saffery C; Fotiadis N; Guettler S; Mansfield D; Melcher A; Powles T; Rao S; Watkins D; Chau I; Matthews N; Wallberg F; Starling N; Cunningham D; Gerlinger M
    J Immunother Cancer; 2019 Apr; 7(1):101. PubMed ID: 30982469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.
    Pishvaian M; Morse MA; McDevitt J; Norton JD; Ren S; Robbie GJ; Ryan PC; Soukharev S; Bao H; Denlinger CS
    Clin Colorectal Cancer; 2016 Dec; 15(4):345-351. PubMed ID: 27591895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers.
    Teijeira A; Migueliz I; Garasa S; Karanikas V; Luri C; Cirella A; Olivera I; Cañamero M; Alvarez M; Ochoa MC; Rouzaut A; Rodriguez-Ruiz ME; Sanmamed MF; Klein C; Umaña P; Ponz M; Bacac M; Melero I
    Theranostics; 2022; 12(3):1373-1387. PubMed ID: 35154495
    [No Abstract]   [Full Text] [Related]  

  • 5. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
    Peters S; Angevin E; Alonso-Gordoa T; Rohrberg K; Melero I; Mellado B; Perez-Gracia JL; Tabernero J; Adessi C; Boetsch C; Watson C; Dal Porto J; Dejardin D; Del Nagro C; Nicolini V; Evers S; Klein C; Leutgeb B; Pisa P; Rossmann E; Saro J; Umana P; Charo J; Teichgräber V; Steeghs N
    Clin Cancer Res; 2024 Apr; 30(8):1630-1641. PubMed ID: 38319672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors.
    Geva R; Vieito M; Ramon J; Perets R; Pedregal M; Corral E; Doger B; Calvo E; Bardina J; Garralda E; Brown RJ; Greger JG; Wu S; Steinbach D; Yao TS; Cao Y; Lauring J; Chaudhary R; Patel J; Patel B; Moreno V
    Cancer Immunol Immunother; 2024 Aug; 73(10):205. PubMed ID: 39105878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of anti-drug antibody responses to the T-cell engaging bispecific antibody cibisatamab to understand the impact on exposure.
    Lotz GP; Lutz A; Martin-Facklam M; Hansbauer A; Schick E; Moessner E; Antony M; Stuchly T; Viert M; Hosse RJ; Freimoser-Grundschober A; Klein C; Schäfer M; Ritter M; Stubenrauch KG
    Front Immunol; 2024; 15():1406353. PubMed ID: 38881900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody.
    Osada T; Hsu D; Hammond S; Hobeika A; Devi G; Clay TM; Lyerly HK; Morse MA
    Br J Cancer; 2010 Jan; 102(1):124-33. PubMed ID: 19953093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB.
    Dudal S; Hinton H; Giusti AM; Bacac M; Muller M; Fauti T; Colombetti S; Heckel T; Giroud N; Klein C; Umaña P; Benincosa L; Bachl J; Singer T; Bray-French K
    J Immunother; 2016 Sep; 39(7):279-89. PubMed ID: 27404941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
    Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
    MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
    Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
    Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
    Bacac M; Fauti T; Sam J; Colombetti S; Weinzierl T; Ouaret D; Bodmer W; Lehmann S; Hofer T; Hosse RJ; Moessner E; Ast O; Bruenker P; Grau-Richards S; Schaller T; Seidl A; Gerdes C; Perro M; Nicolini V; Steinhoff N; Dudal S; Neumann S; von Hirschheydt T; Jaeger C; Saro J; Karanikas V; Klein C; Umaña P
    Clin Cancer Res; 2016 Jul; 22(13):3286-97. PubMed ID: 26861458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
    Gao X; Xu N; Li Z; Shen L; Ji K; Zheng Z; Liu D; Lou H; Bai L; Liu T; Li Y; Li Y; Fan Q; Feng M; Zhong H; Huang Y; Lou G; Wang J; Lin X; Chen Y; An R; Li C; Zhou Q; Huang X; Guo Z; Wang S; Li G; Fei J; Zhu L; Zhu H; Li X; Li F; Liao S; Min Q; Tang L; Shan F; Gong J; Gao Y; Zhou J; Lu Z; Li X; Li J; Ren H; Liu X; Yang H; Li W; Song W; Wang ZM; Li B; Xia M; Wu X; Ji J
    Lancet Oncol; 2023 Oct; 24(10):1134-1146. PubMed ID: 37797632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA.
    Peng L; Oberst MD; Huang J; Brohawn P; Morehouse C; Lekstrom K; Baeuerle PA; Wu H; Yao Y; Coats SR; Dall'Acqua W; Damschroder M; Hammond SA
    PLoS One; 2012; 7(5):e36412. PubMed ID: 22574157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
    Müller D; Karle A; Meissburger B; Höfig I; Stork R; Kontermann RE
    J Biol Chem; 2007 Apr; 282(17):12650-60. PubMed ID: 17347147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy.
    Pan H; Liu J; Deng W; Xing J; Li Q; Wang Z
    Int J Nanomedicine; 2018; 13():3189-3201. PubMed ID: 29881272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.
    Hellmann MD; Kim TW; Lee CB; Goh BC; Miller WH; Oh DY; Jamal R; Chee CE; Chow LQM; Gainor JF; Desai J; Solomon BJ; Das Thakur M; Pitcher B; Foster P; Hernandez G; Wongchenko MJ; Cha E; Bang YJ; Siu LL; Bendell J
    Ann Oncol; 2019 Jul; 30(7):1134-1142. PubMed ID: 30918950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.
    Bartlett NL; Herrera AF; Domingo-Domenech E; Mehta A; Forero-Torres A; Garcia-Sanz R; Armand P; Devata S; Izquierdo AR; Lossos IS; Reeder C; Sher T; Chen R; Schwarz SE; Alland L; Strassz A; Prier K; Choe-Juliak C; Ansell SM
    Blood; 2020 Nov; 136(21):2401-2409. PubMed ID: 32730586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.